Actively Recruiting
Randomized Crossover Study Comparing Bioavailability of Two Oral Elinzanetant Forms in Healthy Women
Led by Bayer · Updated on 2026-08-13
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how two different forms of the medicine elinzanetant are absorbed and processed in healthy women aged 18 to 65 years. The goal is to compare a new tablet form with an existing capsule form to understand any differences in how the body handles these two versions. This study focuses on managing hot flush symptoms related to changes in female hormones. Participants will receive both forms of elinzanetant in a randomized sequence during two treatment periods. Each treatment is taken orally once daily for 10 days within each 12-day period. The study uses a crossover design, meaning each participant receives both treatments at different times, allowing comparison within the same individual. During the study, participants will take the medicine under controlled conditions at a study center, and blood samples will be collected on specific days to measure how the drug is absorbed and processed. Researchers will monitor plasma drug levels and record any treatment-emergent side effects. The entire participation duration covers the two treatment periods with assessments on multiple days to evaluate drug levels and safety.
CONDITIONS
Brief Title
Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants
Research Team
B
Bayer Clinical Trials Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here